Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 431 of 1,261
  1. US 10611760

    Therapeutic compounds as inhibitors of the orexin-1 receptor

    C4X Discovery Limited · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  2. US 10612025

    Antisense oligonucleotides for the treatment of eye disease

    ProQR Therapeutics II B.V. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  3. US 10610486

    Sustained release formulation of a non-steroidal anti-inflammatory drug

    Pacira Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  4. US 10611758

    N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  5. US 10614684

    Treatment of kidney diseases associated with elevated AVP

    THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  6. US 10612045

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  7. US 10612027

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  8. US 10611998

    Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  9. US 10611827

    Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins

    INTEGRATED BIOTHERAPEUTICS, INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  10. US 10611816

    Anti-KRAS-G12D T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  11. US 10611815

    T cell receptors recognizing MHC class II-restricted MAGE-A3

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  12. US 10611851

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  13. US 10611880

    Oxime cross-linked biocompatible polymer hydrogels and methods of use thereof

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  14. US 10611768

    P2X3 and/or P2X2/3 compounds and methods

    Asana BioSciences, LLC · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  15. US 10610583

    Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus

    Regents of the University of Minnesota · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  16. US 10611744

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  17. US 10610597

    Polycarbonates bearing aromatic N-heterocycles for drug delivery

    UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERTSITATEA · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  18. US 10610563

    Use of ubiquitin-proteasome system inhibitors for treatment of tumors associated with neurofibromatosis type-2

    BIOXCEL CORPORATION · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  19. US 10610535

    Diarylpropionitrile therapy for treatment of multiple sclerosis

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  20. US 10612024

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  21. US 10610527

    Methods for treating immunodeficiency disease

    X4 Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  22. US 10610533

    Methods of treating oral mucositis

    Galera Labs, LLC · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  23. US 10610493

    Detoxification using nanoparticles

    The Regents of the University of California · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted
  24. US 10610497

    Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse

    Acurx Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.